heart health
The organizations will codevelop an atrial fibrillation program that provides clinical decision support tools and patient coaching between clinical visits.
The partnership will focus on software that uses ECGs to find left ventricular dysfunction and atherosclerotic cardiovascular disease.
The round comes nearly a year after the company announced it had raised $45 million in Series C financing.
The University Health Network study is being conducted in collaboration with the tech giant, and will enroll roughly 200 patients for three months of active monitoring with a two-year follow-up.
Although beyond the reach of everyday users, an independent study lends support to the Apple Watch's ECG as an option for cardiologists when standard ECGs are unavailable.
The companies will also be looking into using Eko's tech in clinical trials.
The new devices can link to the MyMerlinPulse app and give doctors information about a patient's heart health.
The Fitbit Heart Study is looking to enroll 200,000 to 250,000 device owners, and will support clinical evaluation and regulatory submissions of the company's PPG atrial fibrillation algorithm.
The new funds will be used to expand its coverage outside of New York.
Among more than 400,000 participants who enrolled in the study, only 0.5 percent ever received an atrial fibrillation alert from the app.